Authors: Leor Perl Noa ZemerWassercug Eldad Rechavia Muthiah Vaduganathan Katia Orvin Adaya WeisslerSnir Hila LermanShivek Ran Kornowski Eli I Lev
Publish Date: 2014/08/02
Volume: 39, Issue: 1, Pages: 1-7
Abstract
High ontreatment platelet reactivity HTPR despite use of P2Y12 antagonists is associated with adverse cardiac events The longterm variability in response to prasugrel and ticagrelor is unclear Our aim was to assess residual platelet reactivity PR and rates of HTPR during treatment with prasugrel versus ticagrelor in patients with myocardial infarction MI 114 patients with MI treated with percutaneous coronary intervention PCI were included Sixtytwo patients were treated with prasugrel mean age 58 ± 8 years 21 women 29 diabetes and 52 patients with ticagrelor mean age 63 ± 9 19 women 37 diabetes Patients were tested for PR at 2–4 days and 30 days postPCI using the VerifyNow P2Y12 assay and the multipleelectrode aggregometry Our results show a higher residual PR in patients treated with prasugrel than those treated with ticagrelor VerifyNow 654 ± 606 vs 260 ± 242 P2Y12 reaction units p 0001 at 2–4 days and 673 ± 625 vs 211 ± 261 p 0001 at followup HTPR rates were higher in the prasugrel group 81–113 vs none with ticagrelor in the early test and 87–109 vs none with ticagrelor at followup In conclusion in patients with MI undergoing PCI treatment with ticagrelor resulted in greater platelet inhibition and lower HTPR rates compared with prasugrel up to 30 days after the event
Keywords: